Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This trial will determine the maximum tolerated dose the recommended phase II dose and the
efficacy of this combination in locally advanced or metastatic NSCLC patients